BACKGROUND AND OBJECTIVES: A simple anticoagulation protocol was developed for sustained low-efficiency dialysis (SLED) in patients with AKI, based on the use of anticoagulant citrate dextrose solution formulation A (ACD-A) and standard dialysis equipment. Patients' blood recalcification was obtained from calcium backtransport from dialysis fluid. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All patients treated with SLED (8- to 12-hour sessions) for AKI in four intensive care units of a university hospital were studied over a 30-month period, from May 1, 2008 to September 30, 2010. SLED interruptions and their causes, hemorrhagic complications, as well as coagulation parameters, ionized calcium, and blood citrate levels were recorded. RESULTS: This study examined 807 SLED sessions in 116 patients (mean age of 69.7 years [SD 12.1]; mean Acute Physiology and Chronic Health Evaluation II score of 23.8 [4.6]). Major bleeding was observed in six patients (5.2% or 0.4 episodes/100 person-days follow-up while patients were on SLED treatment). Citrate accumulation never occurred, even in patients with liver dysfunction. Intravenous calcium for ionized hypocalcemia (< 3.6 mg/dl or < 0.9 mmol/L) was needed in 28 sessions (3.4%); in 8 of these 28 sessions (28.6%), low ionized calcium was already present before SLED start. In 92.6% of treatments, SLED was completed within the scheduled time (median 8 hours). Interruptions of SLED by impending/irreversible clotting were recorded in 19 sessions (2.4%). Blood return was complete in 98% of the cases. In-hospital mortality was 45 of 116 patients (38.8%). CONCLUSIONS: This study protocol affords efficacious and safe anticoagulation of the SLED circuit, avoiding citrate accumulation and, in most patients, systematic calcium supplementation; it can be implemented with commercial citrate solutions, standard dialysis equipment, on-line produced dialysis fluid, and minimal laboratory monitoring.
BACKGROUND AND OBJECTIVES: A simple anticoagulation protocol was developed for sustained low-efficiency dialysis (SLED) in patients with AKI, based on the use of anticoagulant citrate dextrose solution formulation A (ACD-A) and standard dialysis equipment. Patients' blood recalcification was obtained from calcium backtransport from dialysis fluid. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: All patients treated with SLED (8- to 12-hour sessions) for AKI in four intensive care units of a university hospital were studied over a 30-month period, from May 1, 2008 to September 30, 2010. SLED interruptions and their causes, hemorrhagic complications, as well as coagulation parameters, ionizedcalcium, and blood citrate levels were recorded. RESULTS: This study examined 807 SLED sessions in 116 patients (mean age of 69.7 years [SD 12.1]; mean Acute Physiology and Chronic Health Evaluation II score of 23.8 [4.6]). Major bleeding was observed in six patients (5.2% or 0.4 episodes/100 person-days follow-up while patients were on SLED treatment). Citrate accumulation never occurred, even in patients with liver dysfunction. Intravenous calcium for ionizedhypocalcemia (< 3.6 mg/dl or < 0.9 mmol/L) was needed in 28 sessions (3.4%); in 8 of these 28 sessions (28.6%), low ionizedcalcium was already present before SLED start. In 92.6% of treatments, SLED was completed within the scheduled time (median 8 hours). Interruptions of SLED by impending/irreversible clotting were recorded in 19 sessions (2.4%). Blood return was complete in 98% of the cases. In-hospital mortality was 45 of 116 patients (38.8%). CONCLUSIONS: This study protocol affords efficacious and safe anticoagulation of the SLED circuit, avoiding citrate accumulation and, in most patients, systematic calcium supplementation; it can be implemented with commercial citrate solutions, standard dialysis equipment, on-line produced dialysis fluid, and minimal laboratory monitoring.
Authors: Mark R Marshall; Thomas A Golper; Mary J Shaver; Muhammad G Alam; Dinesh K Chatoth Journal: Am J Kidney Dis Date: 2002-03 Impact factor: 8.860
Authors: Catherine S C Bouman; Heleen M Oudemans-Van Straaten; Jan G P Tijssen; Durk F Zandstra; Jozef Kesecioglu Journal: Crit Care Med Date: 2002-10 Impact factor: 7.598
Authors: Mark R Marshall; Tianmin Ma; David Galler; Alan Patrick Nigel Rankin; Anthony Brendan Williams Journal: Nephrol Dial Transplant Date: 2004-04 Impact factor: 5.992
Authors: Renato A Caires; Regina C R M Abdulkader; Verônica T Costa E Silva; Gillene S Ferreira; Emmanuel A Burdmann; Luis Yu; Etienne Macedo Journal: J Nephrol Date: 2015-08-23 Impact factor: 3.902
Authors: Abhijat Kitchlu; Neill Adhikari; Karen E A Burns; Jan O Friedrich; Amit X Garg; David Klein; Robert M Richardson; Ron Wald Journal: BMC Nephrol Date: 2015-08-04 Impact factor: 2.388
Authors: Verônica Torres da Costa E Silva; Elerson C Costalonga; Ana Paula Leandro Oliveira; James Hung; Renato Antunes Caires; Ludhmila Abrahão Hajjar; Julia T Fukushima; Cilene Muniz Soares; Juliana Silva Bezerra; Luciane Oikawa; Luis Yu; Emmanuel A Burdmann Journal: PLoS One Date: 2016-03-03 Impact factor: 3.240